Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT07525466RecruitingPhase 1/Phase 2
New drug combination for NK/T-cell lymphoma with immune complications
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
BeijingAges 18 years+ - NCT07528781Recruiting
New 3D Ultrasound Method for Measuring Heart Valve Leakage
This study tests a new way to measure leakage in the mitral valve (a valve in your heart) using advanced 3D ultrasound. If you have moderate or severe mitral valve leakage, this research may help doctors better understand and treat the condition.
Badalona, BarcelonaAges 18–95 - NCT07528352RecruitingPhase 1
Radiation Plus Antibody Therapy for Difficult-to-Treat Lymphoma
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
Salt Lake City, UtahAges 18 years+ - NCT07532941RecruitingPhase 4
Stopping antibiotics early versus completing the full course
This study compares two ways of giving antibiotics to children: stopping when symptoms feel better versus finishing all the prescribed doses. Researchers want to see if stopping early is safe and works just as well, which could help reduce unnecessary antibiotic use.
Melbourne, VictoriaAges 1–17 - NCT07532824RecruitingPhase 1/Phase 2
Proton Radiation and Stem Cell Transplant for High-Risk Blood Cancers
This trial tests a new type of radiation therapy (proton-based) combined with a stem cell transplant from a donor to treat advanced forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to improve survival in patients with aggressive or hard-to-treat disease.
PragueAges 18–65 - NCT07530380RecruitingEarly Phase 1
CAR T-cell therapy for treatment-resistant autoimmune hemolytic anemia
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
HefeiAges 10 years+ - NCT07530640RecruitingPhase 3
Statins to Help Children With Kawasaki Disease Heart Problems
This trial tests whether a cholesterol-lowering medication called atorvastatin can help children whose hearts were damaged by Kawasaki disease (a serious childhood illness that inflames blood vessels). The study may help reduce long-term heart complications.
ShanghaiAges 2–18 - NCT06673290RecruitingPhase 2/Phase 3
Testing different doses of sirolimus for cystic lymphatic malformations
This trial tests different doses of sirolimus (a medication that slows cell growth) to find the best dose for treating cystic lymphatic malformations in children. It may help shrink the abnormal fluid-filled growths and improve symptoms.
Chengdu, SichuanAges 1–18 - NCT06752785RecruitingPhase 1
CAR-T cell therapy for children with ALL and minimal residual disease
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
Guangzhou, GuangdongAges 1–18 - NCT06754267RecruitingPhase 2
Studying a new drug combo for Ph+ B-ALL
This trial tests a combination of three drugs (venetoclax, olverembatinib, and prednisone) for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT06734871RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06755775Recruiting
PET scan to predict immunotherapy success in DLBCL
This trial uses a special PET scan to see if a protein called Granzyme B can predict how well immunotherapy will work for people with DLBCL. It aims to help doctors know earlier if treatment is effective.
ShanghaiAges 18 years+ - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07517133RecruitingPhase 3
Mitapivat for Children With Non-Transfusion-Dependent Thalassemia
This study tests a medicine called mitapivat in children ages 1–17 with thalassemia who don't need frequent blood transfusions. The medicine may help their bodies make more healthy red blood cells and reduce anemia symptoms.
Palo Alto, CaliforniaAges 1–17 - NCT07520006RecruitingPhase 1/Phase 2
NX-5948 With Other Drugs for B-cell Blood Cancers
This early-stage study tests a new drug called NX-5948, given alongside other cancer treatments, for adults with B-cell lymphomas and leukemias (including chronic lymphocytic leukemia, or CLL). The goal is to see if this combination helps control the disease, especially in patients whose cancer has come back or stopped responding to prior treatments.
Aurora, ColoradoAges 18 years+ - NCT07518186RecruitingPhase 3
Comparing Two New Myeloma Treatments: JNJ-79635322 vs Teclistamab
This study compares two new antibody-based drugs (JNJ-79635322 and teclistamab) to see which works better for multiple myeloma that has come back or stopped responding to prior treatment. Both drugs are designed to help your immune system fight myeloma cells.
Birmingham, AlabamaAges 18 years+ - NCT04218318Recruiting
Stopping light therapy early in newborns with blood breakdown
This study looks for a safe threshold to stop the “light therapy” (phototherapy) in newborns who have jaundice caused by blood cell breakdown (hemolytic disease). It may help some babies avoid unnecessary extra days of treatment while still staying safe.
MadinahAges 1 hour–2 weeks - NCT06755619Recruiting
ctDNA testing for response in first-line PCNSL treatment
This study tests whether a blood test (ctDNA) can help doctors see how well treatment is working for people with a type of brain lymphoma (PCNSL) who are getting their first treatment with a cure in mind.
HelsinkiAges 18–70 - NCT07523399Recruiting
Joint Health and Balance in Adults with Hemophilia A
This study looks at how hemophilia A affects joint health, balance, and quality of life in adults. Researchers will assess your joints and balance to understand the relationship between joint damage and everyday function.
VanAges 18–65 - NCT07517510Enrolling by invitationPhase 2
HVA treatment for newly diagnosed mixed-phenotype acute leukemia
This study tests a drug called HVA to treat mixed-phenotype acute leukemia (MPAL), a rare blood cancer that has features of both lymphoblastic and myeloid leukemias. You may qualify if you've just been diagnosed and haven't started strong anti-cancer treatment yet.
Guangzhou, GuangdongAges 18 years+ - NCT07523646RecruitingPhase 4
Blood Boost for Patients With Heart Valve Infections
This study tests whether giving iron and a blood-boosting medicine (EPO) helps patients with bacterial heart valve infections who have low red blood cells. The goal is to see if it speeds recovery and improves how patients feel.
CopenhagenAges 18 years+ - NCT07519811Recruiting
Plain-Language Summaries for Blood and Cancer Patient Letters
This study tests whether simplified, easy-to-read versions of your hospital discharge letters help you better understand your diagnosis and treatment plan. Researchers will ask you questions about the letter to see if the plain-language version works better than the standard medical version.
Munich, BavariaAges 18 years+ - NCT07522905Recruiting
Virtual Movement Therapy for Kids With Leukemia in Remission
This study tests a fun virtual movement program where children who have finished leukemia treatment exercise together with a healthy friend online. The goal is to help improve their physical strength, coordination, and social skills after cancer treatment.
BratislavaAges 5–12 - NCT07516496Recruiting
Understanding Body Chemistry in Vascular Ehlers-Danlos Syndrome
This study looks at how bodies with vascular Ehlers-Danlos syndrome (vEDS) process nutrients and energy differently. By comparing people with vEDS to healthy volunteers, researchers hope to find new ways to manage the condition better.
CambridgeAges 18–85
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.